| protein
| modulator of TFIIH (GTF2H) |
|
MDM2 binding |
|
PIN1 (interaction dependent on the phosphorylation induced by DNA damage) |
|
interacting with TP53INP1 |
|
interacting with MAML1 |
|
interacting with SMARCD1 via its tetramerization domain |
|
interacting with ZBTB2  |
|
physical association between TP53 and BRCA2 may also have important implications in the control of homologous recombination |
|
stabilized in a dose-dependent manner correlating with the level of TP53 target gene expression, by DHRS2 binding to MDM2 |
|
MDM2 binds directly to TP53 to inhibit transcription and export TP53 from the nucleolus to the cytoplasm, resulting in the degradation of TP53 by ubiquitination |
|
MDM2-TP53 interaction is decreased upon deletion, mutation or acetylation of the TP53 C terminus |
|
PBK interacts with the DBD domain of tumor suppressor TP53 and modulates expression of transcriptional targets including CDKN1A |
|
interaction with TP63 (possible functional roles of TP63 in TP53-deficient cancer cells) |
|
antagonistic relationship between NOTCH4 and TP53, which is controlled by the MDM2-dependent ubiquitylation and degradation of the NOTCH receptor |
|
SENP3 interacts with TP53 and MDM2, desumoylates both proteins and bound to the acidic domain of MDM2, which also mediates the TP53 interaction, and competed with TP53 for binding |
|
TP53 regulates autophagy through a direct molecular interaction with RB1CC1, a protein that is essential for the very apical step of autophagy initiation |
|
novel regulator of TP53, modulating low level of MDM2-mediated TP53 ubiquitination in unstressed cells |
|
role of ATF3 as an essential co-transcription factor for TP53 upon DNA damage |
|
binds to the TP53 RE in PARK2 intron 1 and increases PARK2 transcription in cells |
|
novel function for poly(ADP-ribose)ylation of TP53 in the gene-specific regulation of the transcriptional mode of TP53 on the promoter of MTA1 |
|
RECQL4 physically interacts with TP53 only in the absence of DNA damage (TP53-RECQL4 binding leads to the masking of the nuclear localization signal of TP53) |
|
increased TP53 levels upon UBR5 depletion cause a G(1) arrest, as co-depletion of UBR5 and TP53 completely rescues this effect on cell cycle progression |
|
RPL26 and NCL interact with each other and with a double-stranded RNA structure in TP53 mRNA to regulate TP53 translation after stress |
|
E2F1 has an inhibitory role in TP53-mediated apoptosis |
|
NDN required for neuronal development and survival, interacts with both SIRT1 and TP53 to facilitate TP53 deacetylation |
|
TP53 is a target gene of ESR1 (feedback loop between ESR1 and TP53 and a biological role of TP53 in the DNA damage response in ER-positive breast cancers) |
|
TP53-dependent transcriptional up-regulation of its target, E2F7, leads to repression of relevant gene expression |
|
TP53 directly regulates MAF and PROX1, two important transcription factors controlling differentiation in the ocular lens |
|
HEXIM1 interacts with two key TP53 regulators, nucleophosmin and double minute-2 protein (HDM2), implying a possible connection between HEXIM1 and the TP53 signaling pathway |
|
functional interaction between CREBZF and the tumor suppressor TP53 (CREBZF may participate in the modulation of p53 tumor suppressor function) |
|
TP63 but not TP53 is essential for DNA damage triggered transcriptional induction of BBC3 and PMAIP1 in primordial follicle oocytes |
|
RUNX1 acts as a co-activator for TP53 in response to DNA damage |
|
DNAJC7 is associated with TP53 in mammalian cells, and stabilizes TP53 by inhibiting complex formation between TP53 and MDM2 |
|
PRAP1 is a novel TP53 target gene |
|
S100A4 modulates TP53 function in fibroblasts and thereby mediates myocardial interstitial fibrosis through two distinct mechanisms, cell proliferation and collagen expression |
|
KAT6A is an acetylation regulator of TP53 |
|
TP53 rapidly induces VEGFA transcription upon hypoxia exposure by binding, in an HIF1A-dependent manner, to a highly conserved and functional TP53-binding site within the VEGFA promoter |
|
TAF3 functions as an essential coactivator for TP53 |
|
important link between TP53 activation induced by DNA damage and MIRLET7A1 biogenesis |
|
crosstalk between the TGFB1 and TP53 pathways defines a major node of regulation in the cellular stress response, enhancing drug resistance |
|
folding of wild-type TP53 is promoted by an interaction with the chaperonin CCT complex |
|
TP53-ZNF365 axis contributes to genomic stability in the setting of telomere dysfunction |
|
SETD1A, SETD1B and EP300 act cooperatively, through direct interactions and coupled histone modifications, to facilitate the function of TP53 |
|
TXNIP is a new regulator of the ECD-MDM2-TP53 loop |
|
legumain (LGMN) expression and its enzyme activity are regulated by TP53 |
|
RNF38 is an E3 ubiquitin ligase that may play a role in regulating TP53 |
|
TP53 represses expression of the rRNA methyl-transferase fibrillarin (FBL) by binding directly to FBL |
|
CHCHD4 is necessary for the respiratory-dependent translocation of TP53 into the mitochondria |
|
RBM24 is a target gene of the TP53 protein, and can regulate CDKN1A expression via mRNA stability |
|
TOP3A binds to the TP53 and CDKN1A promoters and positively regulates their expression, contributing to the TP53-mediated tumor suppression |
|
TP53& |
|
8209;PIAS3 interaction through the 1-52 amino acid region of TP53, reduces TP53& |
|
8209;MDM2 complex formation, which not only increases the half-life of TP53, but also its transactivation of target genes |
|
JMJD6 antagonizes TP53 acetylation, promotes the association of TP53 with its negative regulator MDM4, and represses transcriptional activity of TP53 |
|
PELP1 interacts with TP53, functions as TP53-coactivator and is required for optimal activation of TP53 target genes under genomic stress |
|
ISG15-dependent degradation of TP53 represents an alternative mechanism of controlling TP53 protein levels |
|
TP73 was required for TP53 stabilization and accumulation under AMPK activation, but was dispensable under DNA damage |
|
TRIM32 interacts with TP53 and promotes TP53 degradation through ubiquitination |
|
XAF1 binds directly to the N-terminal proline-rich domain of TP53 and thus interferes with E3 ubiquitin ligase MDM2 binding and ubiquitination of TP53 |
|
TP53 interacted with C-terminal domain of YWHAG and induced YWHAG ubiquitination |
|
suppression of TP53 by NOTCH3 is mediated by CCNG1 and sustained by MDM2 in hepatocellular carcinoma |
|
HSP90B1 interacts with both TP53 and MDM2 to enhance MDM2-mediated TP53 ubiquitination and degradation |
|
PATZ1, previously known for its transcriptional suppressor functions in T lymphocytes, is a crucial regulator of TP53 |
|
TP53 sequesters TAF9 from GLI1, which may contribute to inhibition of GLI1 activity by TP53 and potentially impact therapeutic success of agents targeting GLI-TAF9 interactions in cancer |
|
KDM8 is a novel binding partner of TP53 and it functions as a positive modulator of cell cycle and cell proliferation mainly through the repression of TP53 pathway |
|
PDCD5 interacts with the TP53 pathway to promote cell apoptosis |
|
TGM2-mediated autophagy and CDKN1A-mediated cell cycle arrest are two important barriers in the TP53 pathway that prevent oncogenic transformation |
|
SIVA1 interacts with tumor protein TP53 and with the member of the tumor necrosis factor receptor superfamily, stathmin, among others |
|
DDB1 silencing activates TP53 pathway and leads to significant effects on cell cycle progression and rapid apoptosis |
|
MYSM1 is a critical negative regulator of TP53 transcriptional programs in hematopoiesis, and its repression of BBC3/PUMA expression is essential for multipotent progenitor (MPP) survival, and partly contributes to maintaining HSC function |
|
like CLCA2, MPZL2 is a type I transmembrane protein that is regulated by TP53 and TP63 |
|
CREBBP and EP300, activate transcription of TP53-regulated stress response genes and stabilize TP53 against ubiquitin-mediated degradation |
|
TRIM65 inactivates TP53 through facilitating TP53 poly-ubiquitination and proteasome-mediated degradation |
|
TP53, a key effector of the DNA damage response, negatively controls RBPJ gene transcription, through suppression of RBPJ promoter activity and, indirectly, by increased CDKN1A expression |
|
CACUL1 is a novel regulator that negatively controls TP53 activity through the regulation of PML SUMOylation |
|
TRIM71 interacts with TP53, controls its abundance by ubiquitination and antagonizes TP53-dependent pro-apoptotic and pro-differentiation response |
|
TP53 played a role in iron homeostasis and was required for FDXR-mediated iron metabolism |
|
SERPINB2 is a direct downstream target of TP53 that is activated by the DNA damage response pathway |
|
direct molecular link between TP53 and DPP4 in the control of lipid metabolism |
|
DDX3 regulates epigenetic transcriptional and translational activation of TP53 and colocalizes with TP53 at centrosome during mitosis to ensure proper mitotic progression and genome stability, which supports the tumor-suppressive role of DDX3X |
|
NINJ1 is a target of TP53 and forms a feedback loop with TP53 by repressing TP53 mRNA translation |
|
expression of USP5 and OTUD6A may be affected by TP53 |
|
TP53 can enhance ferroptosis by inhibiting the expression of SLC7A11 or by enhancing that of SAT1 and GLS2 |
|
TRIM65 binds to the N-terminus of TP53 tumor suppressor and thus competes with MDM2 for TP53 binding |
|
down-regulation of TFAM increases the sensitivity of tumour cells to radiation via TP53/TIGAR signalling pathway |
|
prolyl hydroxylase activity of EGLN3 is dispensable for its ability to stabilize TP53 |
|
LIMCH1 was a negative regulator implicated in the pathogenesis of lung cancer via modulating HUWE1 and TP53 |
|
function for NEK10 in the regulation of TP53 transcriptional activity through tyrosine phosphorylation |
|
NEK10 has recently been shown to phosphorylate TP53 at Y327, promoting cell cycle arrest after exposure to DNA damaging agents |
|
PRPF19 downregulation inhibits MDM4-mediated TP53 inactivation, resulting in induction of cellular senescence 7) |
|
prominent RPA1-interacting partners are the tumor suppressor protein TP53, RAD51, ATRIP and ETAA1 |
